OXU 004
Alternative Names: OXU-004Latest Information Update: 16 Feb 2023
At a glance
- Originator Oxular
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Uveal melanoma
Most Recent Events
- 16 Feb 2023 Discontinued - Preclinical for Uveal melanoma in United Kingdom (Ophthalmic) (Oxular Limited, February 2023)
- 21 Oct 2020 OXU 004 is available for licensing as of 21 Oct 2020. http://www.oxular.com/
- 20 Oct 2020 Oxular has a patent covering the microsphere formulation compositions for the treatment of retinal diseases, in the United Kingdom